Ovarian Cancer Clinical Trial
Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention
To learn if using IGNITE-TX or other intervention (such as educational materials) can help to increase the rates of genetic testing among the family members of people who have been diagnosed with a hereditary cancer syndrome
The primary objectives of this study are to assess the study feasibility by estimating:
The enrollment of probands and (ARRs) at-risk relatives over a 6-month period
The response rate to baseline and follow-up surveys by probands
The response rate to baseline and follow-up surveys by (ARRs) at-risk relatives
The secondary objectives of this study are to:
Measure (ARR) at-risk relatives completion of (CGT) cascade genetic testing among different study arms.
Measure the proportion of enrolled (ARRs) at-risk relatives who make an informed decision about (CGT) cascade genetic testing.
Measure the (ARR) at-risk relatives readiness for (CGT) cascade genetic testing
Measure proband and (ARR) at-risk relatives change in genetics knowledge
Measure proband readiness to communicate results of genetic testing with (ARR) at-risk relatives Secondary objectives in this feasibility study will be primary objectives in a larger study. This feasibility study is not powered to assess these objectives. Including them in this feasibility study will allow for assessment of our measurement tools (surveys from primary objectives) and offer insight into how the intervention may impact cascade genetic testing when implemented on a larger scale
The exploratory objectives in this study are to estimate:
The average website traffic of the IGNITE-TX "Hub" and module completion
The average utilization of family genetic navigators by participants
Estimate the intra-familial correlation (IFC) for (ARR) at-risk relatives completion of (CGT) cascade genetic testing
Assess satisfaction with IGNITE-TX website modules and genetic navigator The exploratory objectives will allow for further evaluation of the IGNITE-TX website modules and navigator and understand how families with multiple (ARR)at-risk relatives respond to the intervention.
18 years of age or older
Speaks and/or reads English or Spanish
Has known deleterious/pathogenic mutation or suspected deleterious/pathogenic variant in BRCA1 or BRCA2 (HBOC) or MLH1, MSH2, MSH6, PMS2, or EPCAM (LS)
Has access to the internet or phone and can send and receive email and/or text messages at a US telephone number
Has at least one at-risk relative who meets inclusion criteria for first-degree relative
Has no at-risk relatives meeting inclusion criteria
Has negative germline genetic testing or only variant of uncertain significance
Unwilling or unable to provide consent 4.2. AT-RISK RELATIVES (ARR)
18 years of age or older
Speaks and reads English or Spanish
Resides in the United States
Can provide proof of deleterious/suspected deleterious HBOC or LS variant present in a first degree relative (biological mother or father, biological child, or full sibling)
Has access to internet or phone and can send and receive email and/or text messages at a US telephone number
Unwilling or unable to provide consent
Reports no known HBOC or LS variant within the family
Has already been tested for the variant identified in the proband
Already listed as an ARR for another proband
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.